Skinvisible Web Sign Up for Updates         T 702.433.7154
Skinvisible - Polymer Delivery System

The Ultimate Polymer Delivery System.

CURRENT LICENSEES:

Over-the-Counter Products Licensed to:

Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ: QNRX) has an exclusive, royalty-bearing license to Skinvisible's technology for select Orphan Rare Skin Diseases and a number of CNS related indications. Currently FDA clinical trials are underway for "QRX003," powered by Skinvisible's Invisicare® proprietary drug delivery technology, to address the challenges of Netherton Syndrome. Skinvisible received $1 million upfront license fee and will receive $5 million and on-going royalties upon Quoin receiving FDA / EU approval.


Womens Choice Pharmaceuticals, a division of ITF Pharma, licensed Skinvisible's topical formulation powered by its Invisicare technology for the prescription treatment for hemorrhoids. Invisicare enhances the delivery of active ingredients by controlling the release and provides superior binding properties. ProCort® is made of a combination of hydrocortisone acetate and pramoxine hydrochloride. Skinvisible has been receiving on-going royalties for ProCort since 2011.


Skinvisible signed an exclusive licensing agreement with Ovation Science Inc. (CSE:OVAT | OTCQB: OVATF) for the use of its Invisicare polymers for cannabis, hemp and hemp seed oil products. In addition, Ovation signed a license to the exclusive worldwide rights to Skinvisible's DermSafe® hand sanitizer made with chlorhexidine gluconate.




Latest Press Releases:


May 29, 2024
Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment

February 14, 2024
Skinvisible Announces Significant Progress In Licensee's Clinical Trials For Invisicare Formulation Targeting Nethertons Syndrome

June 6, 2022
Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug Application



More News...



  Research & Development
  Technology Overview
Home    |     About us    |    Technology    |    Products    |    Investors    |    Contact Us    |    Disclaimer & Privacy    |     Sign Up for Updates
© 2008 Skinvisible Pharmaceuticals, Inc.     Note: This website is not intended for Canadian residents.